Table 3.
Multivariate analysis (Cox Model) on progression-free survival.
| Variable | Hazard ratio (HR) | IC 95% | p-value |
|---|---|---|---|
| PS > 1 | 4.85 | 1.28–18.35 | 0.020 |
| sPD-L1 at first tumor evaluation (continuous variable) | 0.99 | 0.97–1.01 | 0.467 |
| sGranzyme B at nivolumab initiation (continuous variable) | 0.99 | 0.94–1.04 | 0.628 |
| Increase of sPD-L1 concentrations | 4.85 | 1.02-NR | 0.048 |
| Increase sGranzyme B concentrations | 1.82 | 0.61–5.43 | 0.284 |
| IHC PD-L1 positive | 0.79 | 0.26–2.42 | 0.681 |